Welcome
We are thrilled to welcome you to Frontiers of Proteomics 2026, an exclusive evening where leading scientists, industry experts, and innovators come together to explore the latest breakthroughs in proteomics. As Evosep marks its 10-year anniversary, this year’s event is both a celebration of the remarkable progress made across the field and an opportunity to look ahead to the next frontier.
The event will be hosted at Evosep headquarters in Odense, Denmark, on December 7, 2026, from 15:00 to 21:00.
Event Details:
Date
December 7, 2026
Time
15:00 – 21:00
Venue
Evosep Headquarters
Highlights of the Event
- Co-Exhibition Opportunity: Industry partners are invited to co-exhibit roll ups, showcasing your latest innovations and solutions in the field of proteomics.
- Networking: Engage with peers, thought leaders, and customers from the proteomics community in a dynamic environment.
- Dine and Learn: The event will conclude with a dinner, providing an opportunity for relaxed conversations and deeper connections.
This event is not just a meeting of minds but also a celebration of the leaps we have made in proteomics and a look forward to the future we are building together. Your presence would be invaluable as we discuss, deliberate, and dine.
Program
15:00 – 15:30
Meet and greet
15:30 – 15:45
Welcome & Intro
15:45 – 17:15
Keynote speakers
17:15 – 18:00
Guided tour of our HQ
18:00 – 19:30
Networking and exhibition
19:30 – 21:00
Buffet dinner
Keynote speakers
Broken Receptors, Failing Fat, Reversible Blockade: Rare Syndromes as a Guide to Metabolic Disease
Talk by Thilo Samson Chillon, Postdoctoral researcher at OUH Odense
Type 2 diabetes is common and heterogeneous, which makes it difficult to distinguish cause from consequence. In contrast, rare insulin-resistance syndromes isolate specific mechanisms, such as defective insulin receptors, autoantibodies that block them, or failing fat tissue. By profiling the plasma proteome of 117 individuals, we investigated the molecular changes associated with each defect and those that are shared or reversed when the blockade is lifted during remission. Each mechanism has its own protein signature, and a shared extracellular matrix core emerges. During remission, some aspects of the signature normalise, while the extracellular matrix core persists.
Translating Clinical Proteomics into Practice – from discovery to clinical application
Talk by Annelaura Bach Nielsen, Senior Data Scientist at Copenhagen University Hospital
Register for evosep Frontiers event
We cannot wait for you to join our evening event.
